Cardano Risk Management B.V. Reduces Stock Position in Merck & Co., Inc. $MRK

Key Points

• Cardano Risk Management B.V. cut its Merck stake by 1% in the second quarter, selling 9,364 shares and retaining 970,317 shares valued at approximately $124.7 million. Institutional investors collectively own 76.07% of Merck.
• Analysts maintain a favorable outlook, with 13 Buy ratings and seven Holds producing a “Moderate Buy” consensus and an average price target of $134.56, above the reported $128.61 share price.
• Merck beat quarterly estimates with $16.61 billion in revenue and EPS of negative $0.13, while announcing an $0.85 quarterly dividend. However, three executives sold a combined 86,553 shares worth about $11.2 million, and the company faces long-term pressure to diversify ahead of KEYTRUDA’s expected 2028 patent expiration.

Cardano Risk Management B.V. reduced its stake in Merck & Co., Inc. (NYSE:MRK - Free Report) by 1.0% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 970,317 shares of the company's stock after selling 9,364 shares during the period. Merck & Co., Inc. makes up about 1.0% of Cardano Risk Management B.V.'s holdings, making the stock its 27th largest holding. Cardano Risk Management B.V.'s holdings in Merck & Co., Inc. were worth $124,686,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Brighton Jones LLC boosted its stake in Merck & Co., Inc. by 29.5% in the 4th quarter. Brighton Jones LLC now owns 38,278 shares of the company's stock worth $3,808,000 after purchasing an additional 8,710 shares during the period. Sivia Capital Partners LLC grew its holdings in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company's stock valued at $910,000 after buying an additional 3,941 shares in the last quarter. Diversify Advisory Services LLC increased its position in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company's stock valued at $2,590,000 after buying an additional 15,636 shares during the period. Diversify Wealth Management LLC increased its position in shares of Merck & Co., Inc. by 22.2% during the second quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company's stock valued at $3,054,000 after buying an additional 6,897 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Merck & Co., Inc. by 111.7% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company's stock worth $53,918,000 after buying an additional 359,356 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

MRK has been the subject of a number of analyst reports. Citigroup initiated coverage on shares of Merck & Co., Inc. in a research report on Wednesday, May 6th. They issued a "neutral" rating and a $125.00 price objective for the company. Bank of America upped their target price on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the stock a "buy" rating in a report on Tuesday, June 30th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. JPMorgan Chase & Co. raised their price target on shares of Merck & Co., Inc. from $135.00 to $140.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Finally, Wells Fargo & Company boosted their price target on shares of Merck & Co., Inc. from $145.00 to $150.00 and gave the company an "overweight" rating in a research report on Wednesday, July 8th. Thirteen analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to MarketBeat, Merck & Co., Inc. has an average rating of "Moderate Buy" and a consensus target price of $134.56.

Merck & Co., Inc. Price Performance

Shares of NYSE MRK opened at $128.61 on Friday. The stock's 50-day simple moving average is $123.98 and its two-hundred day simple moving average is $119.11. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $135.05. The firm has a market capitalization of $317.64 billion, a P/E ratio of 102.89, a P/E/G ratio of 5.54 and a beta of 0.19. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.05% and a net margin of 4.77%.The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter last year, the company posted $2.13 EPS. The company's revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, equities analysts anticipate that Merck & Co., Inc. will post 2.76 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.6%. Merck & Co., Inc.'s payout ratio is presently 272.00%.

Insider Buying and Selling at Merck & Co., Inc.

In other Merck & Co., Inc. news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the sale, the executive vice president directly owned 46,613 shares in the company, valued at $6,106,303. The trade was a 24.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP David Michael Williams sold 52,847 shares of the business's stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the transaction, the executive vice president directly owned 31,716 shares of the company's stock, valued at approximately $4,084,069.32. This represents a 62.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 86,553 shares of company stock worth $11,177,945 over the last three months. 0.17% of the stock is owned by insiders.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Recent approvals and label-expansion efforts for KEYTRUDA and ENFLONSIA, together with Merck’s raised 2026 revenue outlook, are reinforcing the investment case. One analysis estimates the shares may still be modestly undervalued after a strong recent run. Merck Could Be Undervalued on Raised Outlook and Approvals
• Positive Sentiment: Positive cancer-drug trial readouts and broader strength across biotechnology and pharmaceutical stocks could support investor interest in Merck’s oncology portfolio and pipeline. These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
• Neutral Sentiment: An industry report identifies continued opportunities in endometrial cancer, including frontline immunotherapy combinations, companion diagnostics and precision therapies. The report highlights Merck as a participant but does not announce a new company-specific deal or result. Endometrial Cancer Market Share Analysis and Industry Trends
• Negative Sentiment: Three Merck executive vice presidents reported selling a combined 86,553 shares for approximately $11.2 million. The transactions reduced their individual holdings by roughly 24% to 62%, which may weigh on sentiment, although insider sales do not necessarily indicate a change in company fundamentals. Chirfi Guindo SEC Form 4 David Michael Williams SEC Form 4 David R. Maraldo SEC Form 4
• Negative Sentiment: Merck is working to diversify beyond KEYTRUDA ahead of its expected 2028 patent expiration. The need for acquisitions, partnerships and new growth platforms underscores the long-term revenue risk associated with the company’s largest product. Merck Is Racing Beyond KEYTRUDA

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source